Impact of Antigen Presentation on TCR Modulation and Cytokine Release: Implications for Detection and Sorting of Antigen-Specific CD8+ T Cells Using HLA-A2 Wild-Type or HLA-A2 Mutant Tetrameric Complexes1

Soluble MHC class I molecules loaded with antigenic peptides are available either to detect and to enumerate or, alternatively, to sort and expand MHC class I-restricted and peptide-reactive T cells. A defined number of MHC class I/peptide complexes can now be implemented to measure T cell responses induced upon Ag-specific stimulation, including CD3/CD8/ζ-chain down-regulation, pattern, and quantity of cytokine secretion. As a paradigm, we analyzed the reactivity of a Melan-A/MART-1-specific and HLA-A2-restricted CD8+ T cell clone to either soluble or solid-phase presented peptides, including the naturally processed and presented Melan-A/MART-1 peptide AAGIGILTV or the peptide analog ELAGIGILTV presented either by the HLA-A2 wild-type (wt) or mutant (alanine→valine aa 245) MHC class I molecule, which reduces engagement of the CD8 molecule with the HLA-A2 heavy chain. Soluble MHC class I complexes were used as either monomeric or tetrameric complexes. Soluble monomeric MHC class I complexes, loaded with the Melan-A/MART-1 peptide, resulted in CD3/CD8 and TCR ζ-chain down-regulation, but did not induce measurable cytokine release. In general, differences pertaining to CD3/CD8/ζ-chain regulation and cytokine release, including IL-2, IFN-γ, and GM-CSF, were associated with 1) the format of Ag presentation (monomeric vs tetrameric MHC class I complexes), 2) wt vs mutant HLA-A2 molecules, and 3) the target Ag (wt vs analog peptide). These differences are to be considered if T cells are exposed to recombinant MHC class I Ags loaded with peptides implemented for detection, activation, or sorting of Ag-specific T cells.

[1]  J. Karbach,et al.  Improved detection of melanoma antigen‐specific T cells expressing low or high levels of CD8 by HLA‐A2 tetramers presenting a Melan‐A/Mart‐1 peptide analogue , 2002, International journal of cancer.

[2]  T. Reichert,et al.  Antigen recognition by T cells: a strong sense of structure. , 2001, Trends in immunology.

[3]  J. Becker,et al.  Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. , 2001, Cancer research.

[4]  F. Sallusto,et al.  Antigen decoding by T lymphocytes: from synapses to fate determination , 2001, Nature Immunology.

[5]  Adrian V. S. Hill,et al.  Human CD8+ CTL Specific for the Mycobacterial Major Secreted Antigen 85A1 , 2000, The Journal of Immunology.

[6]  M. Wauben,et al.  Artificial antigen-presenting cells as a tool to exploit the immune `synapse' , 2000, Nature Medicine.

[7]  D. Wiest,et al.  On the dynamics of TCR:CD3 complex cell surface expression and downmodulation. , 2000, Immunity.

[8]  C. Tournay,et al.  Efficient detection and immunomagnetic sorting of specific T cells using multimers of MHC class I and peptide with reduced CD8 binding , 2000, Nature Medicine.

[9]  D. Jäger,et al.  Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[10]  B. Alarcón,et al.  Triggering the TCR complex causes the downregulation of nonengaged receptors by a signal transduction-dependent mechanism. , 2000, Immunity.

[11]  Malin,et al.  Human CD 8 1 CTL Specific for the Mycobacterial Major Secreted Antigen 85 A 1 , 2000 .

[12]  P. Allen,et al.  Partially Phosphorylated T Cell Receptor ζ Molecules Can Inhibit T Cell Activation , 1999, The Journal of experimental medicine.

[13]  B. Seliger,et al.  Cytotoxic T lymphocytes define multiple peptide isoforms derived from the melanoma‐associated antigen MART‐1/Melan‐A , 1999, International journal of cancer.

[14]  L. Samelson,et al.  T cell antigen-receptor signal transduction. , 1999, Current opinion in immunology.

[15]  H. Ploegh,et al.  Peptide antagonism and T cell receptor interactions with peptide-MHC complexes. , 1998, Immunity.

[16]  A. Trautmann,et al.  CD8 expression allows T cell signaling by monomeric peptide-MHC complexes. , 1998, Immunity.

[17]  E. Appella,et al.  Peptides derived from self-proteins as partial agonists and antagonists of human CD8+ T-cell clones reactive to melanoma/melanocyte epitope MART1(27-35). , 1998, Cancer research.

[18]  L. Samelson,et al.  LAT The ZAP-70 Tyrosine Kinase Substrate that Links T Cell Receptor to Cellular Activation , 1998, Cell.

[19]  L. Tuosto,et al.  Quantitative Contribution of CD4 and CD8 to T Cell Antigen Receptor Serial Triggering , 1997, The Journal of experimental medicine.

[20]  R. Zinkernagel,et al.  Peptide‐induced T cell receptor down‐regulation on naive T cells predicts agonist/partial agonist properties and strictly correlates with T cell activation , 1997, European journal of immunology.

[21]  A. Lanzavecchia,et al.  Degradation of  T Cell Receptor (TCR)–CD3-ζ Complexes after Antigenic Stimulation , 1997, The Journal of experimental medicine.

[22]  M. Jackson,et al.  Requirements for Peptide-induced T Cell Receptor Downregulation on Naive CD8+ T Cells , 1997, The Journal of experimental medicine.

[23]  R. Germain,et al.  The Efficiency of CD4 Recruitment to Ligand-engaged TCR Controls the Agonist/Partial Agonist Properties of Peptide–MHC Molecule Ligands , 1997, The Journal of experimental medicine.

[24]  Philip J. R. Goulder,et al.  Phenotypic Analysis of Antigen-Specific T Lymphocytes , 1996, Science.

[25]  A. Casrouge,et al.  Dimerization of soluble major histocompatibility complex-peptide complexes is sufficient for activation of T cell hybridoma and induction of unresponsiveness , 1995, The Journal of experimental medicine.

[26]  A. Lanzavecchia,et al.  Serial triggering of many T-cell receptors by a few peptide–MHC complexes , 1995, Nature.

[27]  J. Renauld,et al.  A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas , 1994, The Journal of experimental medicine.

[28]  P. Parham,et al.  CD8 independence and specificity of cytotoxic T lymphocytes restricted by HLA-Aw68. 1 , 1991, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[29]  P. Parham,et al.  A binding site for the T-cell co-receptor CD8 on the α3 domain of HLA-A2 , 1990, Nature.

[30]  L. Old,et al.  T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[31]  J. Lamb,et al.  Tolerance of T-cell clones is associated with membrane antigen changes , 1983, Nature.

[32]  C. Barnstable,et al.  Monoclonal Antibodies for Analysis of the HLA System , 1979, Immunological reviews.